Tags

Type your tag names separated by a space and hit enter

Olmesartan medoxomil.
Drugs. 2002; 62(9):1345-53; discussion 1354-6.D

Abstract

Olmesartan medoxomil is a nonpeptide angiotensin II receptor antagonist which selectively and competitively inhibits the type 1 angiotensin II receptor without affecting other receptors regulating the cardiovascular system. In well designed randomised trials, olmesartan medoxomil was significantly more effective than placebo, and at dosages of 10 to 20 mg/day was at least as effective as atenolol 50 to 100 mg/day in reducing diastolic blood pressure (DBP). At dosages of 5 to 20 mg/day, olmesartan medoxomil was more effective than captopril 12.5 to 50mg twice daily at lowering seated DBP in patients with mild to moderate hypertension in a dose titration study. Reductions in seated DBP were greater with olmesartan medoxomil 10 to 20 mg/day than losartan 50 to 100 mg/day. Olmesartan medoxomil at 20 mg/day was more effective in lowering seated DBP than losartan 50 mg/day, valsartan 80 mg/day or irbesartan 150 mg/day, and was more efficacious than losartan 50 mg/day or valsartan 80 mg/day at reducing 24-hour ambulatory systolic blood pressure. Olmesartan medoxomil has shown no clinically important pharmacokinetic interactions with digoxin, warfarin or antacid (aluminium magnesium hydroxide). Adverse events were infrequent in clinical studies of olmesartan medoxomil and were similar to those attributed to placebo. With olmesartan medoxomil, the frequency of dizziness was higher than with placebo but similar to that occurring with losartan, valsartan and irbesartan.

Authors+Show Affiliations

Adis International Limited, Auckland, New Zealand. demail@adis.co.nzNo affiliation info available

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

12076183

Citation

Warner, Gregory T., and Blair Jarvis. "Olmesartan Medoxomil." Drugs, vol. 62, no. 9, 2002, pp. 1345-53; discussion 1354-6.
Warner GT, Jarvis B. Olmesartan medoxomil. Drugs. 2002;62(9):1345-53; discussion 1354-6.
Warner, G. T., & Jarvis, B. (2002). Olmesartan medoxomil. Drugs, 62(9), 1345-53; discussion 1354-6.
Warner GT, Jarvis B. Olmesartan Medoxomil. Drugs. 2002;62(9):1345-53; discussion 1354-6. PubMed PMID: 12076183.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Olmesartan medoxomil. AU - Warner,Gregory T, AU - Jarvis,Blair, PY - 2002/6/22/pubmed PY - 2002/8/20/medline PY - 2002/6/22/entrez SP - 1345-53; discussion 1354-6 JF - Drugs JO - Drugs VL - 62 IS - 9 N2 - Olmesartan medoxomil is a nonpeptide angiotensin II receptor antagonist which selectively and competitively inhibits the type 1 angiotensin II receptor without affecting other receptors regulating the cardiovascular system. In well designed randomised trials, olmesartan medoxomil was significantly more effective than placebo, and at dosages of 10 to 20 mg/day was at least as effective as atenolol 50 to 100 mg/day in reducing diastolic blood pressure (DBP). At dosages of 5 to 20 mg/day, olmesartan medoxomil was more effective than captopril 12.5 to 50mg twice daily at lowering seated DBP in patients with mild to moderate hypertension in a dose titration study. Reductions in seated DBP were greater with olmesartan medoxomil 10 to 20 mg/day than losartan 50 to 100 mg/day. Olmesartan medoxomil at 20 mg/day was more effective in lowering seated DBP than losartan 50 mg/day, valsartan 80 mg/day or irbesartan 150 mg/day, and was more efficacious than losartan 50 mg/day or valsartan 80 mg/day at reducing 24-hour ambulatory systolic blood pressure. Olmesartan medoxomil has shown no clinically important pharmacokinetic interactions with digoxin, warfarin or antacid (aluminium magnesium hydroxide). Adverse events were infrequent in clinical studies of olmesartan medoxomil and were similar to those attributed to placebo. With olmesartan medoxomil, the frequency of dizziness was higher than with placebo but similar to that occurring with losartan, valsartan and irbesartan. SN - 0012-6667 UR - https://www.unboundmedicine.com/medline/citation/12076183/Olmesartan_medoxomil_ L2 - https://dx.doi.org/10.2165/00003495-200262090-00005 DB - PRIME DP - Unbound Medicine ER -